Inhibitors of cellular necrosis and related methods
A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
1. A compound having the following structure (Ia):
or a pharmaceutically acceptable salt or tautomer thereof.
2. A pharmaceutical composition comprising a compound having the following structure (Ia):
or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
3. A method of inhibiting receptor interacting protein kinase 1 (RIP1 kinase) in a subject, the method comprising administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a compound having the following structure (Ia):
or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
4. The compound of claim 1 having the following structure (Ia):
or a pharmaceutically acceptable salt thereof.
5. A method of inhibiting receptor interacting protein kinase 1 (RIP1 kinase) in a subject, the method comprising delivering an effective amount of the compound of claim 1 .
6. The compound of claim 1 , (R)-5-((7-chloro-6-fluoro-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione.